New antibody combo aims to stall multiple Myeloma's return
NCT ID NCT06508983
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This phase 3 trial tests whether adding an experimental drug called SG301 to two standard medications (pomalidomide and dexamethasone) can help people with multiple myeloma that has come back or stopped responding to treatment. About 360 adults aged 18–75 with measurable disease and prior therapy will receive either SG301 or a placebo alongside the standard drugs. The study measures safety, side effects, and how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SG301 (a monoclonal antibody) combined with pomalidomide and dexamethasone
- What this could lead to
- If successful, this combination could offer a new treatment option that delays cancer progression in people with multiple myeloma that has returned or not responded to prior therapy.
- What could go wrong
- This is an early-stage phase 3 trial, so results are not yet known. The drug may cause side effects or fail to improve outcomes compared to standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Chaoyang Hospital of Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100024, China
Contact
Contact
-
First Affiliated Hospital of Henan University of Science and Technology
RECRUITINGLuoyang, Henan, 471000, China
Contact
Contact
-
Guangzhou First People's Hospital
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510000, China
Contact
Contact
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450000, China
Contact
Contact
-
Shanxi Provincial Hospital
RECRUITINGTaiyuan, Shanxi, 030000, China
Contact
Contact
-
Sun Yat-sen University Cancer Center
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510000, China
Contact
Contact
-
The First Affiliated Hospital Of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact
Contact
-
The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital)
RECRUITINGXi’an, Shanxi, 710000, China
Contact
Contact
-
The Second Affiliated Hospital Zhejiang University School Of Medicine
RECRUITINGHangzhou, Zhejiang, 310056, China
Contact
Contact
-
Tianjin Cancer University Airport Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact
Contact
-
Tianjin Medical University Cancer Institute & Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact
Contact
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
Contact
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World data may reveal best Second-Line therapy for multiple myeloma
- New universal cell therapy shows promise for Hard-to-Treat blood cancer
- Experimental NK cell therapy for blood cancers hits early hurdle
- New CAR-T therapy RN9101 targets Hard-to-Treat myeloma
- Vitamin c boost: could it make chemo safer for myeloma patients?
- Can a Pre-Dose prevent a dangerous reaction in multiple myeloma treatment?